Company Overview and News

4
CDC: 14 Million Americans Will Have Alzheimer’s by 2060

2018-09-21 biospace
Incidence of Alzheimer’s disease is projected to double in the next 40 years unless a cure or preventive measures are found. The U.S. Centers for Disease Control and Prevention (CDC) published a new report in the journal Alzheimer’s & Dementia projecting the disease’s likely expansion, and for the first time, forecasted the disease by race and ethnicity.
AXON

4
Axovant to Present at Two Upcoming Investor Conferences

2018-09-20 globenewswire
BASEL, Switzerland, Sept. 20, 2018 (GLOBE NEWSWIRE) -- Axovant Sciences (NASDAQ:AXON) today announced that Pavan Cheruvu, M.D., chief executive officer, will present a corporate overview at the Jefferies Gene Therapy Summit 2018 on September 27, 2018 at 9:45 a.m. ET. Additionally, Dr. Cheruvu will participate in a fireside chat at the Chardan Annual Genetic Medicines Conference 2018 on October 9, 2018 at 3:15 p.
AXON

9
OXFORD BIOMEDICA PLC INTERIM RESULTS FOR THE SIX MONTHS ENDED 30 JUNE 2018

2018-09-13 globenewswire
Oxford, UK – 13 September 2018: Oxford BioMedica plc (“Oxford BioMedica” or “the Group”) (LSE: OXB), a leading gene and cell therapy group, today announces interim results for the six months ended 30 June 2018.
IMDZ OXB LNSTY OXBDF AXON

4
Vivek Ramaswamy's Urovant Files for IPO to Raise $150 Million

2018-09-11 biospace
Urovant Sciences, a Vivek Ramaswamy company under the Roivant umbrella, has filed for an initial public offering (IPO) to raise $150 million. It will list on Nasdaq under the UROV symbol.
AXON

5
Axovant to Present at Upcoming Investor Conferences

2018-08-29 globenewswire - 1
BASEL, Switzerland, Aug. 29, 2018 (GLOBE NEWSWIRE) -- Axovant Sciences (NASDAQ: AXON) today announced that Pavan Cheruvu, M.D., chief executive officer, will participate in two upcoming investor conferences. Dr Cheruvu will present a corporate overview at the H.C. Wainwright 20th Annual Global Investment Conference on September 5, 2018 at 10:25 a.m. ET. He will also participate in a fireside chat at the Baird 2018 Global Healthcare Conference on September 6, 2018 at 1:25 p.
AXON

4
AXON / Axovant Sciences Ltd. null

2018-08-28 sec.gov
begin 644 filename1.pdf M)5!$1BTQ+C4-)>+CS],-"C0Y(# @;V)J#3P\+TQI;[email protected](O5'EP92]84F5F+U=;,2 R(#%=/CYS=')E86T-"FC>8F)[email protected] M8F#R A(,4X [email protected](")[email protected]<0G"P8F1H8#(%D&1G3B/^/D/P [email protected]"T60;D M#0IE;F1S=')E86T-96YD;V)J#7-T87)T>')[email protected]*, T*)25%3T8-"B @(" @ M(" @#0HV,2 P(&]B:@T\/"]#(#8Y+T9I;'1E
AXON

4
AXON / Axovant Sciences Ltd. FORM 8-K (Current Report)

2018-08-17 sec.gov
Document UNITED STATES
AXON

4
AXON / Axovant Sciences Ltd. AXON FORM S-8 08162018

2018-08-16 sec.gov
Document As filed with the Securities and Exchange Commission on August 16, 2018
AXON

10
What Is Going On At Axovant Sciences?

2018-08-15 seekingalpha - 2
On February 12, 2018, Axovant Sciences (AXON) issued a press release noting changes to the management team and Board of Directors. Dr David Hung retired as CEO and Dr Pavan Cheruvu took his place, among other changes. Three and a half months of radio silence followed. What broke the silence? Another press release on May 29 noting additions to the management team and organizational restructuring. Things got interesting on June 6, when AXON reported it had licensed a gene therapy for Parkinson’s disease from Oxford BioMedica and of course made additional management changes.
ACAD OXB OXBDF AXON

4
AXON / Axovant Sciences Ltd. 8-K (Current Report)

2018-08-08 sec.gov
Document UNITED STATES
AXON

4
AXON / Axovant Sciences Ltd. DEF 14A

2018-07-24 sec.gov
TABLE OF CONTENTS
AXON

39
Your Daily Pharma Scoop: Voyager Advances, Roche Succeeds, Eisai Positive

2018-07-19 seekingalpha - 2
Voyager advancing gene therapy for Parkinson's, Phase 2 data may be sufficient for U.S. marketing application
SGEN AST RCUS ACIU BAX CLRBZ CLRBW VYGR PULM TRPX CLRB AXON

9
Options Traders Expect Huge Moves in Axovant Sciences (AXON) Stock

2018-07-16 zacks - 2
Investors in Axovant Sciences Ltd. (AXON - Free Report) need to pay close attention to the stock based on moves in the options market lately. That is because the Aug 17, 2018 $2.50 Call had some of the highest implied volatility of all equity options today. What is Implied Volatility? Implied volatility shows how much movement the market is expecting in the future. Options with high levels of implied volatility suggest that investors in the underlying stocks are expecting a big move in one direction or the other.
GTT KRYS AXON

AXON : Axovant Sciences Stock Analysis and Research Report

2017-11-09 - Asif

Axovant Sciences is a clinical-stage biopharmaceutical company dedicated to advancing treatments for patients with life-altering neurologic conditions. To date, its primary focus has been on developing intepirdine, an orally administered antagonist of the 5-HT 6 receptor, for the treatment of Alzheimer's disease and dementia with Lewy bodies, or DLB, and its second product candidate, nelotanserin, a potent and highly selective inverse agonist of the 5-HT 2A receptor, for the treatment of visual hallucinations in patients with Lewy body dementia, or LBD, movement disorder symptoms in patients with DLB and REM behavior disorder, or RBD, in patients with LBD. In September 2017, the company announced that the Phase 3 MINDSET clinical trial of 35 mg intepirdine in patients with mild-to-moderate Alzheimer's disease who were receiving background donepezil therapy did not meet its co-primary efficacy endpoints. Axovant Sciences is continuing to advance the products in its pipeline, focusing on...

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

Silicon Investor Message Boards

This table lists all message boards related to AXON / Axovant Sciences Ltd. on message board site Silicon Investor.

Axon Enterprise, Inc. (AAXN), formerly Taser Intl. Axon Enterprise, Inc. (AAXN), formerly Taser Intl. Axon Enterprise, Inc. (AAXN), formerly Taser Intl. Axonyx Inc (AXYX) Axonyx Inc (AXYX) Axonyx Inc (AXYX)
Axion Spatial Imaging Ltd. (AXON) Axion Spatial Imaging Ltd. (AXON) Axion Spatial Imaging Ltd. (AXON) Axonyx Inc. (NasdaqSC:AXYX) Axonyx Inc. (NasdaqSC:AXYX) Axonyx Inc. (NasdaqSC:AXYX)
Saxon Petroleum (SXN-TSE) Saxon Petroleum (SXN-TSE) Saxon Petroleum (SXN-TSE)
CUSIP: G0750W104